MUMBAI, India, Oct. 26, 2021 /PRNewswire/ UNI/ Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of its novel, patent protected, globally researched Sodium Glucose Co-Transporter Inhibitor (SGLT2i) – Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, with Metformin (first-line medication for the treatment of type 2 diabetes). This fixed drug combination is indicated for the management of Type 2 diabetes. The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo MV and Remozen MV.

Glenmark is the first company in the world to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination (FDC) and India is the first country to get access to this FDC drug. Glenmark received approval from the DCGI (the drug approval authority in India) for manufacturing and marketing this fixed dose combination in late September 2021.

Globally, SGLT2 inhibitors & DPP4 inhibitors are emerging as the preferred treatment option for the management of Type 2 diabetes. Glenmark has been at the forefront in providing access to the latest treatments at a low cost for patients with diabetes in India.

Glenmark’s FDC of Remogliflozin + Vildagliptin + Metformin tackles most of the pathophysiology in Type 2 Diabetes that makes it an appealing fixed dose combination in managing uncontrolled Type 2 Diabetes. Mono components of the FDC are recommended by AACE guideline for early use in the hierarchy of Anti diabetic medications for management of Type 2 diabetes. Further, FDC of SGLT2i + DPP4i + Metformin is currently first & only triple drug FDC considered rational for approval by US FDA.

In chronic diseases like Type 2 diabetes, patients are required to consume multiple anti-diabetic drugs for prolonged periods of time. Moreover, in India, patients have to bear the drug cost on their own and so the price of the drug becomes a major factor that impacts treatment adherence. While the average daily cost of therapy of existing brands in the same drug category (when clubbed together for price comparison) is around Rs. 75, Glenmark’s Remogliflozin + Vildagiptin + Metformin combination has been launched at a breakthrough price of Rs. 16.50 per tablet, to be taken twice daily; which amounts to Rs.33.00 as the per day cost of therapy. This cost is atleast 53% lower than the other available SGLT2 & DPP4 combination drugs administered along with Metformin, in India¹.

Glenmark’s Remogliflozin + Vildagliptin + Metformin combination will significantly improve access and bring a world class and well researched combination product at an affordable price to patients in India. This combination has been approved by the DCGI, the drug regulator in India for adults aged 18 years and older with Type 2 diabetes to improve glycemic control when metformin and one of the mono-components of fixed dose combination do not provide adequate glycemic control, or when already being treated with separate doses of Remogliflozin, Vildagliptin and Metformin.

“Globally, SGLT2i + DPP4i + Metformin FDCs are emerging as a preferred treatment for management of type-2 diabetes. Diabetes is a key focus area for Glenmark and we have been at the forefront in providing access to the latest treatment options to diabetes patients in India. We are proud to introduce this innovative fixed dose combination, which is cutting-edge, extensively researched, at an affordable cost and will significantly improve patient compliance and provide glycemic & extra glycemic benefits to patients with uncontrolled Type 2 diabetes, in India,“ said Mr. Alok Malik, Group Vice President & Business Head, India Formulations.

In 2015, Glenmark revolutionized the diabetes market by launching its DPP4 inhibitor – Teneligliptin at a price that was approximately 55% lower than the other DPP4 inhibitors available in India at that time. Continuing the legacy, Glenmark launched its globally researched, innovator molecule Remogliflozin in 2019, at a price around 55% lesser than other SGLT2 inhibitors available in the Indian market at that time. In 2020, Glenmark became the first company in the world to launch Remogliflozin (100 mg) + Vildagliptin (50 mg) Fixed Dose Combination (FDC).

According to the International Diabetes Federation (IDF), the prevalence of diabetes in India is 8.9% with around 77 million adults living with diabetes as of 2019².

References:

^1.  https://www.1mg.com/

^2.  https://idf.org/our-network/regions-members/south-east-asia/members/94-india.html

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited (Glenmark) is a global research-led pharmaceutical company with presence across generics, specialty and OTC businesses and with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It ranks among the world’s top 50 Generics and Biosimilars companies (Top 50 Company Rankings, 2020, from Informa’s Generics Bulletin). The company has been listed on the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry being featured in the index.

Kolkata, Oct 25 (UNI) Tata AIA Life Insurance (Tata AIA Life) is adding 100 new branches to
expand its distribution reach across the country.

The Insurer currently has over 218 branches across 25 states and 175 cities of the country,
while having a strong presence in the agency, broking, bancassurance, assisted purchase and
online space, according to a statement here today.
Through this expansion, the Insurer will expand its reach significantly in over 18 Indian states, especially Maharashtra, Gujarat, Rajasthan, Uttar Pradesh, and West Bengal. Over 60 of the 100
new digitally enabled branches have already begun operations, with the remaining to become operational by end of October’21.
The step is part of Tata AIA Life’s business growth strategy to expand its distribution as well as customer connect points and contribute to industry efforts towards increasing life insurance
penetration in the country. The expansion is expected to contribute to significant growth.
Each branch has been enabled with digital solutions and processes to facilitate contactless
customer service and paperless operations. Customers can interact with branch officials through
video calls or if visiting the branch, can avail of a self-service digital kiosk, to get their needs
serviced and queries addressed. Such digitization of physical branches will also help in sustaining physical distancing protocols.
Speaking on the occasion, Naveen Tahilyani, MD & Chief Executive Officer, Tata AIA Life
Insurance, said, “More and more consumers are realising the need to avail protection and
savings-oriented solutions today, as we navigate these challenging times. Amid this scenario,
we, at Tata AIA, are making sure that we can service consumers through various modes,
especially through conveniently located branches in emerging locations. Given that these
branches are digitally enabled, they will allow us to meet the evolving needs of the new age
consumers, while also supporting the Government’s efforts to deepen life insurance
penetration and maintain safety protocols and procedures with regards to the continuing
pandemic.”
Amit Dave, Chief Agency Officer, Tata AIA Life Insurance, added, “70 out of the 100 new
digitally enabled are being introduced in locations where we do not have an existing agency
distribution setup. This will enable us to expand our reach and offer our protection & saving
related solutions to the local populace in these markets. Importantly, the move should lead
to generation of over 10,000 jobs, directly with employees on payroll and indirectly as
bringing onboard digitally enabled and highly trained life insurance advisors.”

Kolkata, Oct 25 (UNI) 5paisa.com today announced the launch of its unique service – ‘5paisa Wealth’,
a new professional portfolio advisory service for their clientele.
5paisa.com is the first broker in the country to introduce portfolio advisory services for its customers, according to a statement here.
The new offering includes portfolios from leading investment advisors with proven track records. 5paisa clients can invest in these fee-based baskets to add diversification to their long-term equity portfolios.
The portfolios are created and managed by the research teams at Abakkus Investment Advisors (led by Mr. Sunil Singhania) & Alpha Portfolios (a division of Renaissance Investment Managers, led by Mr. Pankaj Murarka).

Sunil Singhania, the founder of Abakkus, has a distinguished track record of over two decades in Equity Investments. Formerly, as CIO-Equities, he played an instrumental role in building Reliance-Nippon MF into one of India’s largest AMCs overseeing ~USD 11bn of equity assets.
Pankaj Murarka has over 25 years of experience in Equity Research & Fund Management with credible track record of performance over his professional career. In his last role, Pankaj was associated with Axis Mutual Fund as the Chief Investment Officer (CIO) managing over $2bn in Indian Equities.
Prakarsh Gagdani, CEO at 5paisa.com, says, “A large section of retail investors coming to the capital market – be it for the first time or those who have been in the market for some time, are looking for expert advice for their investment. Despite being in the markets, they are not clear in terms of where to invest, how to invest and how to maximize the returns on their investments and look for expert advice. Though Mutual Funds is an option, there is a section of investors who look for active participation under expert guidance.”
“5paisa Wealth aims to target that segment of investors who have a surplus of Rs 2.5 lakhs and are looking for the best fund managers in town. We are glad to associate ourselves with Sunil Singhania
led Abakkus, and Pankaj Murarka led Renaissance to partner with them to provide fund management services under 5paisa Wealth.”
The Abakkus Smart Flexicap portfolio consists of growth companies from the top 250 stocks picked via a bottom-up approach, where profitability is expected to grow higher than the market averages.
Singhania said, “We are excited to launch Abakkus Smart Advisory portfolio’s to 2mn customers of 5paisa.” Abakkus Manages around Rs6000 Cr in PMS/AIF and the team has around 150 years of cumulative experience of tracking Equities and other markets across the globe. The Alpha Core and Satellite portfolio comprises a blend of long-term secular growth businesses and cyclical & sectoral businesses that are likely to benefit in the prevailing economic cycle.”
Murarka said, “We are excited to partner 5paisa Wealth and being able to bring our advisory portfolios to clients of 5paisa Wealth. 5paisa is amongst the fastest growing digital broking platform
in India and in a short span it has emerged as India’s leading Digital Broking Platform. The launch of 5paisa Wealth marks the next leap in the journey of building wealth management platform for digitally native customers. Renaissance Investment Managers is excited to participate in this journey and through this alliance we endeavour to offer clients – best in class high quality advisory portfolios
which are transparent, low cost with seamless experience.”
Renaissance Investment Managers is an equity focused and long-term wealth creation investment house managing customer assets and generating exceptional returns for its investors by identifying great investment ideas. Catering to around 1000+ customers and garnering an AUM of around
Rs. 500 Cr, Renaissance was founded in 2016.
These portfolios have a pricing model that is based on the investment value of the client in that portfolio. The composition of these portfolios will be reviewed regularly by the managers to ensure
that it continues to reflect the underlying strategy. 5paisa users can invest and track these portfolios
on an ongoing basis on a single platform